Spotlight Innovation Inc. entered into a Research Agreement with the University of Alabama at Birmingham to conduct studies to validate the efficacy of Spotlight Innovation's Immunoplex immunotherapy platform technology for metastatic breast cancer in mouse models. These pre-clinical studies are anticipated to take approximately six months and are intended to validate significant and highly favorable prior test data. The data will be submitted as part of an Investigational New Drug filing with the U.S. Food and Drug Administration.

Lyse A. Norian, PhD, is the Principal Investigator. Dr. Norian conducted the original studies during her tenure at the University of Iowa. The study protocol includes the examination of primary tumor growth in mice, the examination of metastatic tumor growth in mice with resected primary tumors, and analyses of tumor-infiltrating and systemic leukocytes in tumor-bearing mice.